

2nd Quarter 2025 Injectable Medication HCPCS/DOFR Crosswalk

Use the updates for dates of service on and after December 2, 2025

The Pharmacy Advisory Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. The Pharmacy Advisory Committee members include physicians and pharmacists.

The approved updates, effective December 2, 2025 are listed on pages 2-6 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net* and CalViva Health *Provider Participation Agreement (PPA)*.

The update includes:

- 16 new injectable medications to be added to the DOFR crosswalk
- 40 updates and changes to current injectable medication procedure codes
- 15 new biosimilars and updates to be added to the DOFR Crosswalk
- 3 updates for new generic drugs

Additional information

Relevant sections of the Plan's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on the provider portal at provider.healthnetcalifornia.com > *Provider Library* under Quick Links, or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center listed in the right hand column.

THIS UPDATE APPLIES TO:

- Participating Physician Groups

PROVIDER SERVICES

CalViva Health Medi-Cal
(including ECM and CS providers) –
888-893-1569

PROVIDER PORTAL

provider.healthnetcalifornia.com

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

New drugs

| HCPCS | Drug name | Generic name | Primary category | Secondary category |
|-------|-----------------|---|-----------------------|-------------------------------------|
| J0172 | Azmiro™ | Injection, testosterone cypionate, 1 milligrams (mg) | Therapeutic injection | |
| J9999 | Emrelis™ | Telisotuzumab vedotin-tllv for injection, for intravenous (IV) use | Therapeutic injection | Chemotherapy ¹ |
| J3590 | Encelto™ | Revakinagene taroretcel-lwey intravitreal implant 200,000 cells | Therapeutic injection | |
| A9611 | Flyrcado™ | Flurpiridaz F 18 IV solution 5-55 mCi/ milliliters (ml) (190-2,050 megabecquerels (MBq)/ml) | Diagnostic agent | Not included in DOFR crosswalk |
| J9999 | Grafapex™ | Treosulfan for injection for IV use | Therapeutic injection | Chemotherapy ¹ |
| J3590 | Imaavy™ | Nipocalimab-Aahu IV solution | Therapeutic injection | |
| J9249 | Ivra™ | Melphalan HCl IV solution 90 mg/ml (base equivalent) | Therapeutic injection | Chemotherapy ¹ |
| J0364 | Onapgo™ | Apomorphine hydrochloride (HCl) solution cartridge | Self-injectable | |
| J9999 | Penpulimab-kcqx | Penpulimab-kcqx injection for IV use | Therapeutic injection | Chemotherapy ¹ |
| J3490 | Qfitlia™ | Fitusiran injection for subcutaneous use | Therapeutic injection | Blood/blood products for hemophilia |
| J2547 | Rapiblyk™ | Landiolol HCl for IV solution 280 mg | Therapeutic injection | |
| J3590 | Ryoncil® | Remestemcel-L-rknd 2 x 3.8 ml suspension for IV infusion kit | Therapeutic injection | |
| J9342 | Tepadina® | Injection, thiotepa, not otherwise specified, 1 mg | Therapeutic injection | Chemotherapy ¹ |
| J9341 | Tepylute® | Thiotepa for IV solution | Therapeutic injection | Chemotherapy ¹ |
| J9275 | Unloxcyt™ | Injection, cosibelimab-ipdl, 2 mg | Therapeutic injection | Chemotherapy ¹ |
| 90593 | Vimkunya™ | Chikungunya vaccine recombinant virus-like particle IM suspension pre-filled syringe 40 mcg/0.8ml | Therapeutic injection | Immunization |

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

Updates/changes to injectable medication procedure codes or HCPCS codes

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

| HCPCS | Drug name | Generic name | Comment |
|-------|--------------------------------|---|---------------------------------------|
| J3303 | Aristospan® intra-articular | Triamcinolone hexacetonl injection | Code deleted |
| Q2058 | Aucatzyl® | Obecabtagene autoleucel suspension for intravenous infusion | Replaces J3590 |
| J3355 | Bravelle® | Urofollitropin, 75 international unit (IU) | Discontinued |
| 90684 | Capvaxive™ | Pneumococcal 21-valent conjugate vaccine injection, for intramuscular use | Replaces J3590 |
| J1020 | Depo-medrol® 20 | Methylprednisolone 20 mg injection | Code deleted |
| J1030 | Depo-medrol® 40 | Methylprednisolone 40 mg injection | Code deleted |
| J1040 | Depo-medrol® 80 | Methylprednisolone 80 mg injection | Code deleted |
| J1010 | Depo-medrol® | Injection, methylprednisolone acetate, 1 mg | New code replaces J1020, J1030, J1040 |
| J1100 | Dexamethasone sodium phosphate | Dexamethasone sodium phosphate 1 mg | Code deleted |
| J1180 | Dilor | Dyphylline injection | Discontinued |
| C9304 | Hympavzi™ | Marstacimab-hncq injection, for subcutaneous use | Replaces J3590 |
| J3391 | Lenmeldy™ | Atidarsagene autotemcel IV suspension | Replaces J3590 |
| J3490 | Luveris® | Lutropin alfa for subcutaneous injection 75 unit | Discontinued |
| J2919 | Solu-medrol® | Methylprednisolone sodium succinate for injection PF 500 | Code deleted |
| J9289 | Opdivo qvantig™ | Nivolumab and hyaluronidase-nvhy injection, for subcutaneous use | Replaces J9999 |
| J0725 | Profasi® | Chorionic gonadotropin/1000 IU | Discontinued |
| J0725 | Profasi HP® | Chorionic gonadotropin/1000 IU | Discontinued |
| J3590 | Repronex® | Menotropins 75 IU | Discontinued |

Updates/changes to injectable medication procedure codes or HCPCS codes, *continued*

| HCPCS | Drug name | Generic name | Comment |
|--------------|-----------------------------|---|----------------|
| Q9998 | Selarsdi™ | ustekinumab-aekn is biosimilar* to Stelara® | Replace J3590 |
| J1720 | Solu-cortef® | Hydrocortisone sodium succinate | Code deleted |
| Q5099 | Steqeyma® | Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg | Replaces J3590 |
| J1590 | Tequin® | Gatifloxacin injection | Discontinued |
| J2725 | Thyrel® TRH | Protirelin per 250 mcg | Discontinued |
| S0040 | Ticarcillin | Ticarcillin disodium | Discontinued |
| J0365 | Trasyol® | Aprotonin, 10,000 Kallikrein Inactivator Units (KIU) | Discontinued |
| J3301 | Triamcinolone acetonide USP | Triamcinolone acetonide injection | Code deleted |
| J1642 | Vasceze™ | Heparin sodium injection per 10 USP | Discontinued |
| 90393 | Vaccinia | Vaccinia immune globulin (VIG), human, intramuscular (IM) | Discontinued |
| J0900 | Valertest #1 | Testosterone enanthate and estradiol valerate | Discontinued |
| J3372 | Vancomycin | Injection, vancomycin hydrochloride | New code |
| J3400 | Vesprin | Triflupromazine hydrochloride (HCl) injection | Discontinued |
| J9219 | Viadur® | Leuprolide acetate implant | Discontinued |
| J7356 | Vyalev™ | Foslevodopa-foscarbidopa subcutaneous injection | Replaces J3490 |
| Q5100 | Yestintek™ | Injection, ustekinumab-kfce (yesintek), biosimilar, 1mg | Replaces J3590 |
| J0691 | Xenleta™ | Lefamulin injection, for intravenous use | Discontinued |
| J7513 | Zenapax® | Daclizumab 25 mg, parenteral | Discontinued |
| 90736 | Zostavax™ | Zoster (shingles) vaccine, live, for subcutaneous injection | Discontinued |
| J9276 | Ziihera® | Zanidatamab-hrii injection IV solution | Replaces J9999 |
| J2311 | Zimhi™ | Injection, naloxone HCl, 1 mg | Replaces J2310 |
| C9303 | Vyloy® | Zolbetuximab-clzb | Replaces J9999 |

New biosimilars to be added to the DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

| HCPCS | Drug name | Generic name | Primary category | Secondary category |
|-------|------------|---|-----------------------|--------------------------------------|
| J3590 | Bomynta® | Denosumab 120mg/1.7ml, injection, for subcutaneous use (biosimilar to Xgeva®) | Therapeutic injection | Chemotherapy adjunctive ¹ |
| J3590 | Conexence® | Denosumab-bnht injection, for subcutaneous use (biosimilar to Prolia®) | Therapeutic injection | |
| Q5098 | Imuldosa™ | Injection, ustekinumab-srlf, (biosimilar for Stelara), 1 mg | Self-injectable | |
| Q5136 | Jubbonti® | Denosumab-bbdz injection solution prefilled syringe (biosimilar to Prolia) | Therapeutic injection | |
| J3590 | Jobevne™ | Bevacizumab-nwgd injection, (biosimilar to Avastin®) | Therapeutic injection | |
| Q5153 | Opuviz™ | Aflibercept-yszy injection, for intravitreal use (biosimilar to Eylea®) | Therapeutic injection | |
| Q9999 | Otulfi™ | Ustekinumab-aaaz solution prefilled syringe 45 mg/0.5ml (biosimilar to Stelara) | Self-injectable | |
| Q9999 | Otulfi™ | Ustekinumab-aaaz solution prefilled syringe 90 mg/ml (biosimilar to Stelara) | Self-injectable | |
| Q9999 | Otulfi™ | Injection, ustekinumab-aaaz, biosimilar to Stelara, 1 mg, IV | Therapeutic injection | |
| Q5142 | Simlandi® | Adalimumab-ryvk injection (biosimilar to Humira®), 1 mg | Self-injectable | |
| Q9996 | Pyzchiva® | Injection, ustekinumab-ttwe, subcutaneous, 1 mg biosimilar to Stelara | Self-injectable | |
| Q9997 | Pyzchiva® | Injection, ustekinumab-ttwe, IV, 1 mg biosimilar to Stelara | Therapeutic injection | |
| Q9998 | Selarsdi™ | Injection, ustekinumab-aekn, 1 mg, biosimilar to Stelara | Self-injectable | |

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

New biosimilars to be added to the DOFR crosswalk, *continued*

| HCPCS | Drug name | Generic name | Primary category | Secondary category |
|--------------|------------------|--|-------------------------|---------------------------|
| J3590 | Steqeyma® | Injection, ustekinumab-stba, biosimilar to Stelara, 1 mg | Self-injectable | |
| Q5150 | Ahzantive® | Injection, aflibercept-mrbb, biosimilar to Eylea 1 mg | Therapeutic injection | |

New generic injectable medications

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

| HCPCS | Drug name | Generic name | Primary category | Secondary category |
|--------------|------------------------------|--|-------------------------|--------------------------------------|
| J0616 | Metoprolol | Injection, metoprolol tartrate, 1 mg | Therapeutic injection | |
| J1954 | Leuprolide acetate for depot | Injection, leuprolide acetate for depot suspension (ciplā), 7.5 mg | Therapeutic injection | Chemotherapy adjunctive ¹ |
| J1954 | Leuprolide acetate for depot | Injection, leuprolide acetate for depot suspension (ciplā), 7.5 mg | Therapeutic injection | Chemotherapy adjunctive ¹ |

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at <http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html>.